Reacción a "Using triptans for migraine during pregnancy does not increase risk of neurodevelopmental disorders in offspring"

Triptans are contraindicated during pregnancy in their European medicine leaflet because pregnant women with migraine were not included in their clinical trials. However, it is not uncommon for women taking them to become pregnant and continue taking them in early pregnancy, and migraine can reportedly worsen in 8% of pregnant women. 

A previous independent Norwegian registry of pregnant women with migraine treated with triptans and two post-marketing pharmaceutical industry registries had demonstrated their safety in newborns and with respect to mode of delivery. However, there was no large study on the possibility of long-term neurodevelopmental disease and this study confirms safety again in newborns, but also gives us unique data on neurodevelopmental safety in childhood and adolescence. 

It should be noted that the developmental disorders that have been ruled out are clinical disorders, i.e. diagnosed by someone. A psychological study has not been carried out to detect less serious or subclinical disorders. 

This work reassures patients and physicians about the longer-term safety of triptans, but does not change their contraindication during pregnancy.